Last reviewed · How we verify
Study of Adjunctive Recombinant Human Interleukin-2 Therapy in Patients With MDR-TB (rhIL-2)
Multidrug-resistant tuberculosis (MDR-TB) has emerged as a challenge worldwide. Few studies have prospectively reported outcomes in patients with pulmonary MDR-TB treated with adjunctive immunotherapy combined to standard chemotherapy. We aimed to assess whether immunotherapy with Interleukin(IL)-2 enhanced the clinical and immune effects of treatment on MDR-TB patients.We performed a multicentre prospective cohort study extend all over Jiangsu province in China. Two groups were generated based on the adjunctive rhIL-2 therapy during 24 months regiman. Bacteriological and imaging data were followed during 24 months with cure rates analysed.
Details
| Lead sponsor | The First Affiliated Hospital with Nanjing Medical University |
|---|---|
| Phase | PHASE2, PHASE3 |
| Status | UNKNOWN |
| Enrolment | 500 |
| Start date | Mon Jun 01 2009 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Sun Mar 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- MDR TB
Interventions
- RhIL-2
Countries
China